Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model

Citations Over TimeTop 12% of 2014 papers

Abstract

In the atavistic model of cancer progression, tumor cell dedifferentiation is interpreted as a reversion to phylogenetically earlier capabilities. The more recently evolved capabilities are compromised first during cancer progression. This suggests a therapeutic strategy for targeting cancer: design challenges to cancer that can only be met by the recently evolved capabilities no longer functional in cancer cells. We describe several examples of this target-the-weakness strategy. Our most detailed example involves the immune system. The absence of adaptive immunity in immunosuppressed tumor environments is an irreversible weakness of cancer that can be exploited by creating a challenge that only the presence of adaptive immunity can meet. This leaves tumor cells more vulnerable than healthy tissue to pathogenic attack. Such a target-the-weakness therapeutic strategy has broad applications, and contrasts with current therapies that target the main strength of cancer: cell proliferation.

Related Papers

• → Interrelationship between inflammatory cytokines (IL-1, IL-6, IL-33, IL-37) and acquired immunity.(2019)28 cited
• → Vertebrate Immune Systems(2023)2 cited
• → Perceptions of Investment Risk Associated with Material Control Weakness Pervasiveness and Disclosure Detail(2010)36 cited
• → Persisting adaptive immunity to SARS-CoV-2 in Lower Austria(2021)4 cited
• → The Adaptive Immunity(2016)